Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 397 articles:
HTML format



Single Articles


    May 2020
  1. GLEESON M, Counsell N, Cunningham D, Lawrie A, et al
    Prognostic indices in diffuse large B-cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R-CHOP 14 versus 21 phase 3 trial.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16691.
    PubMed     Abstract available


  2. MCKAY P, Wilson MR, Chaganti S, Smith J, et al
    The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2020 May 20. doi: 10.1111/bjh.16866.
    PubMed     Abstract available


  3. CARREAU NA, Armand P, Merryman RW, Advani RH, et al
    Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy.
    Br J Haematol. 2020 May 19. doi: 10.1111/bjh.16756.
    PubMed     Abstract available


  4. SHIVAROV V, Ivanova M
    Clinical outcomes of composite and sequential B-cell lymphomas with features intermediate between DLBCL/PMBCL and classical Hodgkin Lymphoma from the SEER database.
    Br J Haematol. 2020 May 18. doi: 10.1111/bjh.16728.
    PubMed    


  5. BADAR T, Astle J, Kakar IK, Zellner K, et al
    Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression.
    Br J Haematol. 2020 May 16. doi: 10.1111/bjh.16738.
    PubMed    


  6. KIMBY E, Lockmer S, Holte H, Hagberg H, et al
    The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16692.
    PubMed     Abstract available


  7. MASSARO F, Stepanishyna Y, Manni M, Luminari S, et al
    Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16714.
    PubMed     Abstract available


  8. LEE S, Fujita K, Morishita T, Negoro E, et al
    Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma.
    Br J Haematol. 2020 May 14. doi: 10.1111/bjh.16743.
    PubMed     Abstract available


  9. SONNEVI K, Wasterlid T, Melen CM, Harrysson S, et al
    Survival of very elderly patients with diffuse large B-cell lymphoma according to treatment intensity in the immunochemotherapy era: a Swedish Lymphoma Register study.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16737.
    PubMed     Abstract available


  10. PEPRAH S, Ogwang MD, Kerchan P, Reynolds SJ, et al
    Mean platelet counts are relatively decreased with malaria but relatively increased with endemic Burkitt Lymphoma in Uganda, Tanzania, and Kenya.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16700.
    PubMed     Abstract available


  11. CALIMERI T, Ferreri AJM
    Prevention of CNS relapse in diffuse large B-cell lymphoma: common sense prevails where science fails.
    Br J Haematol. 2020 May 12. doi: 10.1111/bjh.16719.
    PubMed    


  12. EPPERLA N
    What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid.
    Br J Haematol. 2020 May 9. doi: 10.1111/bjh.16726.
    PubMed    


  13. INOUE H, Rai S, Tanaka H, Espinoza JL, et al
    Tumour-immune microenvironment in duodenal-type follicular lymphoma.
    Br J Haematol. 2020 May 8. doi: 10.1111/bjh.16715.
    PubMed     Abstract available


  14. O'KELLY B, McGettrick P, Angelov D, Fay MP, et al
    Outcome of a patient with refractory Hodgkin's Lymphoma on pembrolizumab, infected with SARS-CoV-2.
    Br J Haematol. 2020 May 7. doi: 10.1111/bjh.16798.
    PubMed     Abstract available


    April 2020
  15. LEE ATJ, Attygale AD, Sharma RK, Iyengar S, et al
    LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy.
    Br J Haematol. 2020 Apr 27. doi: 10.1111/bjh.16679.
    PubMed    


  16. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available


  17. AHMED S, Ghosh N, Ahn KW, Khanal M, et al
    Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma.
    Br J Haematol. 2020 Apr 21. doi: 10.1111/bjh.16664.
    PubMed     Abstract available


  18. SMYTH L, Blunt DN, Gatov E, Nagamuthu C, et al
    Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large population-based study of 4913 subjects.
    Br J Haematol. 2020 Apr 17. doi: 10.1111/bjh.16635.
    PubMed     Abstract available


  19. GOTO H, Hirano N, Inoue M, Takano K, et al
    Immune escape by loss of heterozygosis of HLA genes facilitated the transmission of diffuse large B cell lymphoma from mother to offspring.
    Br J Haematol. 2020 Apr 17. doi: 10.1111/bjh.16662.
    PubMed    


  20. AU-YEUNG RKH, Arias Padilla L, Zimmermann M, Oschlies I, et al
    Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.
    Br J Haematol. 2020 Apr 2. doi: 10.1111/bjh.16578.
    PubMed     Abstract available


    March 2020
  21. MARTINEZ-CALLE N, Poynton E, Alchawaf A, Kassam S, et al
    Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Br J Haematol. 2020 Mar 31. doi: 10.1111/bjh.16592.
    PubMed     Abstract available


  22. PAINSCHAB MS, Westmoreland KD, Tomoka T
    Improving outcomes for non-Hodgkin lymphoma in Sub-Saharan Africa: where to start?
    Br J Haematol. 2020 Mar 24. doi: 10.1111/bjh.16617.
    PubMed    


  23. MEZGER NCS, Feuchtner J, Griesel M, Hammerl L, et al
    Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa.
    Br J Haematol. 2020 Mar 17. doi: 10.1111/bjh.16575.
    PubMed     Abstract available


  24. FOWLER NH, Nastoupil L, De Vos S, Knapp M, et al
    The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
    Br J Haematol. 2020 Mar 16. doi: 10.1111/bjh.16424.
    PubMed     Abstract available


  25. BISHTON MJ, Rule S, Wilson W, Turner D, et al
    The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
    Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16555.
    PubMed     Abstract available


  26. D'ALO F, Malafronte R, Piludu F, Bellesi S, et al
    Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
    Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16563.
    PubMed    


  27. DOORDUIJN JK, Zijlstra JM, Lugtenburg PJ, Kersten MJ, et al
    Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
    Br J Haematol. 2020 Mar 9. doi: 10.1111/bjh.16567.
    PubMed     Abstract available


  28. MOLETI ML, Testi AM, Foa R
    Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2020 Mar 6. doi: 10.1111/bjh.16461.
    PubMed     Abstract available


  29. LOPEZ-DIAZ DE CERIO A, Garcia-Munoz R, Pena E, Panizo A, et al
    Maintenance therapy with ex vivo expanded lymphokine-activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression.
    Br J Haematol. 2020 Mar 4. doi: 10.1111/bjh.16474.
    PubMed     Abstract available


  30. PARSONS KE, Goodlad JR, Leach M
    Bone marrow involvement by nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2020 Mar 2. doi: 10.1111/bjh.16464.
    PubMed    


    February 2020
  31. PLATTEL WJ, Visser L, Diepstra A, Glaudemans AWJM, et al
    Interim thymus and activation regulated chemokine versus interim (18) F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.
    Br J Haematol. 2020 Feb 27. doi: 10.1111/bjh.16514.
    PubMed     Abstract available


  32. HONG H, Fang X, Huang H, Wang Z, et al
    The derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2020 Feb 27. doi: 10.1111/bjh.16447.
    PubMed     Abstract available


  33. DALAL NH, Dores GM, Curtis RE, Linet MS, et al
    Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia, 2000-2016.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16492.
    PubMed     Abstract available


  34. RODDAY AM, Hahn T, Kumar AJ, Lindenauer PK, et al
    First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study.
    Br J Haematol. 2020 Feb 23. doi: 10.1111/bjh.16525.
    PubMed     Abstract available


  35. MUSSOLIN L, Lovisa F, Gallingani I, Cavallaro E, et al
    Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
    Br J Haematol. 2020 Feb 20. doi: 10.1111/bjh.16531.
    PubMed    


  36. ABRAHAO R, Li QW, Malogolowkin MH, Alvarez EM, et al
    Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study.
    Br J Haematol. 2020 Feb 20. doi: 10.1111/bjh.16539.
    PubMed     Abstract available


  37. KIRIMUNDA S, Verboom M, Otim I, Ssennono M, et al
    Variation in the Human Leukocyte Antigen system and risk for endemic Burkitt lymphoma in northern Uganda.
    Br J Haematol. 2020 Feb 18. doi: 10.1111/bjh.16398.
    PubMed     Abstract available


  38. JAIN MD, Lam R, Liu Z, Stubbins RJ, et al
    Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder.
    Br J Haematol. 2020 Feb 18. doi: 10.1111/bjh.16304.
    PubMed     Abstract available


  39. EKBERG S, E Smedby K, Glimelius I, Nilsson-Ehle H, et al
    Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study.
    Br J Haematol. 2020 Feb 17. doi: 10.1111/bjh.16489.
    PubMed     Abstract available


  40. MONDELAERS V, Ferster A, Uyttebroeck A, Brichard B, et al
    Prospective, real-time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma in Belgium.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16495.
    PubMed     Abstract available


  41. LEE HJ, Schmelz JL, Cramer F, Romaguera JE, et al
    A phase I study of carfilzomib in combination with ibrutinib for relapsed refractory mantle cell lymphoma.
    Br J Haematol. 2020 Feb 14. doi: 10.1111/bjh.16378.
    PubMed    


  42. LACASCE AS, Bociek RG, Sawas A, Caimi P, et al
    Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
    Br J Haematol. 2020 Feb 12. doi: 10.1111/bjh.16499.
    PubMed    


  43. PICKARD K, Williams C, Watson H, McGregor A, et al
    Leukaemic relapse of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2020 Feb 9. doi: 10.1111/bjh.16475.
    PubMed    


  44. REEDIJK AMJ, Zijtregtop EAM, Coebergh JWW, Meyer-Wentrup FAG, et al
    Improved survival for adolescents and young adults with Hodgkin lymphoma and continued high survival for children in the Netherlands: a population-based study during 1990-2015.
    Br J Haematol. 2020 Feb 6. doi: 10.1111/bjh.16491.
    PubMed     Abstract available


  45. SMITH SD, Till BG, Shadman MS, Lynch RC, et al
    Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
    Br J Haematol. 2020 Feb 6. doi: 10.1111/bjh.16494.
    PubMed     Abstract available


  46. AUSSEDAT G, Traverse-Glehen A, Stamatoullas A, Molina T, et al
    Composite and sequential lymphoma between classical Hodgkin lymphoma and primary mediastinal lymphoma/diffuse large B-cell lymphoma, a clinico-pathological series of 25 cases.
    Br J Haematol. 2020 Feb 6. doi: 10.1111/bjh.16331.
    PubMed     Abstract available


  47. JAKOBSEN LH, Ellin F, Smeland KB, Wasterlid T, et al
    Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
    Br J Haematol. 2020 Feb 4. doi: 10.1111/bjh.16425.
    PubMed     Abstract available


  48. MENTER T, Tzankov A, Zucca E, Kimby E, et al
    Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy.
    Br J Haematol. 2020 Feb 3. doi: 10.1111/bjh.16414.
    PubMed     Abstract available


  49. MCCULLOCH R, Visco C, Eyre TA, Frewin R, et al
    Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    Br J Haematol. 2020 Feb 3. doi: 10.1111/bjh.16416.
    PubMed     Abstract available


    January 2020
  50. HUANG D, Song TL, Nairismagi ML, Laurensia Y, et al
    Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
    Br J Haematol. 2020 Jan 31. doi: 10.1111/bjh.16435.
    PubMed     Abstract available


  51. EL-GALALY TC, Cheah CY
    Mantle cell lymphoma - where precision medicine based on response-adapted treatment strategies could show its full worth.
    Br J Haematol. 2020 Jan 30. doi: 10.1111/bjh.16396.
    PubMed    


  52. SCHORB E, Fox CP, Kasenda B, Linton K, et al
    Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
    Br J Haematol. 2020 Jan 29. doi: 10.1111/bjh.16451.
    PubMed     Abstract available


  53. YUAN S, Wang Y, Luo H, Jiang Z, et al
    Serum soluble VSIG4 as a surrogate marker for the diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis.
    Br J Haematol. 2020 Jan 21. doi: 10.1111/bjh.16299.
    PubMed     Abstract available


  54. WITTE HM, Merz H, Biersack H, Bernard V, et al
    Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
    Br J Haematol. 2020 Jan 20. doi: 10.1111/bjh.16342.
    PubMed     Abstract available


  55. LOLLI G, Argnani L, Broccoli A, Marangon M, et al
    (90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study.
    Br J Haematol. 2020 Jan 13. doi: 10.1111/bjh.16404.
    PubMed    


    December 2019
  56. DUFFLES AMARANTE G, Collins G, Rocha V
    What do we know about duodenal-type follicular lymphoma? From pathological definition to treatment options.
    Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16348.
    PubMed     Abstract available


  57. PETTENGELL R, Dlugosz-Danecka M, Andorsky D, Belada D, et al
    Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
    Br J Haematol. 2019 Dec 27. doi: 10.1111/bjh.16255.
    PubMed     Abstract available


  58. RODGERS TD, Baran A, Reagan PM, Casulo C, et al
    Efficacy of lenalidomide in high-risk diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Dec 17. doi: 10.1111/bjh.16302.
    PubMed    


  59. HAYDEN AR, Lee DG, Villa D, Gerrie AS, et al
    Validation of a simplified international prognostic score (IPS-3) in patients with advanced-stage classic Hodgkin lymphoma.
    Br J Haematol. 2019 Dec 10. doi: 10.1111/bjh.16293.
    PubMed     Abstract available


  60. KORULA A, Devasia AJ, Kulkarni U, Abubacker FN, et al
    Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting.
    Br J Haematol. 2019 Dec 7. doi: 10.1111/bjh.16289.
    PubMed     Abstract available


  61. LANDSBURG DJ, Ayers EC, Bond DA, Maddocks KJ, et al
    Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy.
    Br J Haematol. 2019 Dec 5. doi: 10.1111/bjh.16319.
    PubMed     Abstract available


  62. WALEWSKI J, Paszkiewicz-Kozik E, Michalski W, Rymkiewicz G, et al
    First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
    Br J Haematol. 2019 Dec 2. doi: 10.1111/bjh.16264.
    PubMed     Abstract available


    November 2019
  63. BENTO L, Diaz-Lopez A, Barranco G, Martin-Moreno AM, et al
    New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO).
    Br J Haematol. 2019 Nov 28. doi: 10.1111/bjh.16263.
    PubMed     Abstract available


  64. ROSADAS C, Puccioni-Sohler M, Oliveira ACP, Casseb J, et al
    Adult T-cell leukaemia/lymphoma in Brazil: A rare disease or rarely diagnosed?
    Br J Haematol. 2019 Nov 19. doi: 10.1111/bjh.16318.
    PubMed    


  65. JEON YW, O JH, Park KS, Min GJ, et al
    Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
    Br J Haematol. 2019 Nov 16. doi: 10.1111/bjh.16257.
    PubMed     Abstract available


  66. GLIMELIUS I, Smedby KE, Eloranta S, Jerkeman M, et al
    Comorbidities and sex differences in causes of death among mantle cell lymphoma patients - A nationwide population-based cohort study.
    Br J Haematol. 2019 Nov 13. doi: 10.1111/bjh.16317.
    PubMed     Abstract available


  67. TOWNSEND W, Leong S, Hoskin P, Diez P, et al
    Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
    Br J Haematol. 2019 Nov 11. doi: 10.1111/bjh.16296.
    PubMed     Abstract available


  68. THIEBLEMONT C, Howlett S, Casasnovas RO, Mounier N, et al
    Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
    Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300.
    PubMed     Abstract available


  69. POSTHUMA HLA, Zijlstra JM, Visser O, Lugtenburg PJ, et al
    Primary therapy and survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma: a population-based analysis in the Netherlands, 1993-2016.
    Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16290.
    PubMed     Abstract available


    October 2019
  70. MAHALE P, Herr MM, Engels EA, Pfeiffer RM, et al
    Autoimmune conditions and primary central nervous system lymphoma risk among older adults.
    Br J Haematol. 2019 Oct 17. doi: 10.1111/bjh.16222.
    PubMed     Abstract available


  71. LAGERLOF I, Holte H, Glimelius I, Bjorkholm M, et al
    No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
    Br J Haematol. 2019 Oct 14. doi: 10.1111/bjh.16232.
    PubMed     Abstract available


  72. KALOYANNIDIS P, Hertzberg M, Webb K, Zomas A, et al
    Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
    Br J Haematol. 2019 Oct 6. doi: 10.1111/bjh.16201.
    PubMed     Abstract available


  73. GARCIA-MUNOZ R, Quero C, Perez-Persona E, Domingo-Garcia A, et al
    Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study.
    Br J Haematol. 2019 Oct 1. doi: 10.1111/bjh.16227.
    PubMed     Abstract available


    September 2019
  74. CASTELLINO SM, Parsons SK, Kelly KM
    Closing the survivorship gap in children and adolescents with Hodgkin lymphoma.
    Br J Haematol. 2019 Sep 30. doi: 10.1111/bjh.16197.
    PubMed     Abstract available


  75. DI RAIMONDO C, Abdulla FR, Zain J, Querfeld C, et al
    Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type.
    Br J Haematol. 2019 Sep 30. doi: 10.1111/bjh.16211.
    PubMed    


  76. ADAMS HJA, Kwee TC
    Value of detecting bone marrow involvement in Hodgkin lymphoma.
    Br J Haematol. 2019 Sep 16. doi: 10.1111/bjh.16181.
    PubMed    


  77. ZANELLI M, Bertuzzi C, Zizzo M, Martino G, et al
    Extracavitary primary effusion lymphoma in a post-transplantation patient.
    Br J Haematol. 2019 Sep 13. doi: 10.1111/bjh.16196.
    PubMed    


  78. BAZARBACHI A, Boumendil A, Finel H, Castagna L, et al
    Influence of donor type, stem cell source and conditioning on outcomes after haploidentical transplant for lymphoma - a LWP-EBMT study.
    Br J Haematol. 2019 Sep 9. doi: 10.1111/bjh.16182.
    PubMed     Abstract available


  79. PEDERSEN MA, Gormsen LC, d'Amore F
    Value of detecting bone marrow involvement in Hodgkin lymphoma - Response to Adams and Kwee.
    Br J Haematol. 2019 Sep 4. doi: 10.1111/bjh.16180.
    PubMed    


  80. KANATE AS, Savani BN
    Who is the best relative - optimizing haploidentical donor transplantation in lymphoma?
    Br J Haematol. 2019 Sep 2. doi: 10.1111/bjh.16178.
    PubMed    


  81. DUNLEAVY K
    Epigenetic targeting in mantle cell lymphoma.
    Br J Haematol. 2019;186:805-806.
    PubMed    


    August 2019
  82. PASSERO FC JR, Ravi D, McDonald JT, Beheshti A, et al
    Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
    Br J Haematol. 2019 Aug 26. doi: 10.1111/bjh.16160.
    PubMed     Abstract available


  83. LOCKMER S, Ren W, Brodtkorb M, Ostenstad B, et al
    M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.
    Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16159.
    PubMed     Abstract available


  84. R WILSON M, McKay P, Leach M
    Primary leptomeningeal B-cell lymphoma.
    Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16163.
    PubMed    


  85. MELLERT K, Martin M, Lennerz JK, Ludeke M, et al
    The impact of SOCS1 mutations in diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Aug 12. doi: 10.1111/bjh.16147.
    PubMed     Abstract available


  86. MESGUICH C, Roch A, Hindie E, Milpied N, et al
    Prognostic utility of pre-transplantation [(18) F] fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma who underwent rituximab, dexamethasone, high-dose cytarabine, carboplatin salvage che
    Br J Haematol. 2019 Aug 6. doi: 10.1111/bjh.16144.
    PubMed     Abstract available


  87. PULSONI A, Della Starza I, Cappelli LV, Tosti ME, et al
    Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy.
    Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16125.
    PubMed     Abstract available


  88. VANNATA B, Conconi A, Winkler J, Cascione L, et al
    Late relapse in patients with diffuse large B-cell lymphoma: impact of rituximab on their incidence and outcome.
    Br J Haematol. 2019 Aug 5. doi: 10.1111/bjh.16106.
    PubMed     Abstract available


    July 2019
  89. MAGNANO L, Lopez-Guillermo A
    Minimal residual disease - ready for prime time in follicular lymphoma?
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16119.
    PubMed    


  90. FERRETTI A, Baldacci E, Miulli E, Canichella M, et al
    Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma.
    Br J Haematol. 2019 Jul 31. doi: 10.1111/bjh.16114.
    PubMed    


  91. KONDO E, Shimizu-Koresawa R, Chihara D, Mizuta S, et al
    Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplant
    Br J Haematol. 2019 Jul 29. doi: 10.1111/bjh.16115.
    PubMed    


  92. DEMAGNY J, Guiheneuf E, Joris M, Garcon L, et al
    Hodgkin lymphoma infiltration with associated haemophagocytosis in bone marrow films.
    Br J Haematol. 2019 Jul 29. doi: 10.1111/bjh.16108.
    PubMed    


  93. WILSON MR, Bagguley T, Smith A, Roman E, et al
    Frontline management of nodular lymphocyte predominant Hodgkin lymphoma - a retrospective UK multicentre study.
    Br J Haematol. 2019 Jul 25. doi: 10.1111/bjh.16109.
    PubMed    


  94. GUIDEZ S, Lacotte-Thierry L, Tomowiak C, Princet I, et al
    Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Jul 15. doi: 10.1111/bjh.16056.
    PubMed    


  95. DOMINGUEZ-PINILLA N, Martinez-Zamorano E, Campos-Martin Y, Algara Plana P, et al
    Paediatric-type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia.
    Br J Haematol. 2019 Jul 8. doi: 10.1111/bjh.16089.
    PubMed    


  96. MATSUE K, Abe Y, Narita K, Kobayashi H, et al
    Diagnosis of intravascular large B-cell lymphoma: novel insights into clinicopathological features from 42 patients at a single institution over 20 years.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16081.
    PubMed     Abstract available


  97. PRUSILA REI, Sorigue M, Jauhiainen J, Mercadal S, et al
    Risk of secondary haematological malignancies in patients with follicular lymphoma: an analysis of 1028 patients treated in the rituximab era.
    Br J Haematol. 2019 Jul 3. doi: 10.1111/bjh.16090.
    PubMed     Abstract available


  98. YORDANOVA K, Stilgenbauer S, Bohle RM, Lesan V, et al
    Spontaneous regression of a plasmablastic lymphoma with MYC rearrangement.
    Br J Haematol. 2019 Jul 1. doi: 10.1111/bjh.16082.
    PubMed    


    June 2019
  99. LEE S, Fujita K, Negoro E, Morishita T, et al
    The impact of diagnostic wait time on the survival of patients with diffuse large B-cell lymphoma: effect modification by the International Prognostic Index.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16078.
    PubMed     Abstract available


  100. SAKAMOTO K, Shiba N, Deguchi T, Kiyokawa N, et al
    Negative CD19 expression is associated with inferior relapse-free survival in children with RUNX1-RUNX1T1-positive acute myeloid leukaemia: results from the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16080.
    PubMed     Abstract available


  101. CARRARO E, Mussolin L, Onofrillo D, Massano D, et al
    The revised International Paediatric Non-Hodgkin Lymphoma Staging System (IPNHLSS): a test of applicability.
    Br J Haematol. 2019 Jun 27. doi: 10.1111/bjh.16079.
    PubMed    


  102. IKEDA C, Maruyama D, Oka H, Fujino T, et al
    Bone marrow involvement by monomorphic epitheliotropic intestinal T-cell lymphoma.
    Br J Haematol. 2019 Jun 25. doi: 10.1111/bjh.16073.
    PubMed    


  103. WIGHT JC, Yue M, Keane C, Johnston A, et al
    Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance.
    Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16064.
    PubMed     Abstract available


  104. BLOMBERY P, Birkinshaw RW, Nguyen T, Gong JN, et al
    Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.
    Br J Haematol. 2019 Jun 24. doi: 10.1111/bjh.16069.
    PubMed    


  105. DJEBBARI F, Browning JA, Stanton L, Booth S, et al
    Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Jun 20. doi: 10.1111/bjh.16071.
    PubMed    


  106. ROY SF, Ghazawi FM, Powell J, Kokta V, et al
    EBV-associated hydroa vacciniforme-like T-cell lymphoma.
    Br J Haematol. 2019 Jun 19. doi: 10.1111/bjh.16065.
    PubMed    


  107. ONG DM, Ashby M, Grigg A, Gard G, et al
    Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B-cell lymphoma receiving rituximab-chemotherapy combinations.
    Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16049.
    PubMed     Abstract available


  108. KATO H, Kato K, Kim SW, Fukuda T, et al
    Clinical outcomes of hepatitis B or C virus infections in patients with malignant lymphoma receiving autologous stem cell transplantation: on behalf of the Adult Lymphoma Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHC
    Br J Haematol. 2019 Jun 17. doi: 10.1111/bjh.16050.
    PubMed    


  109. KELLY KM, Cole PD, Pei Q, Bush R, et al
    Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group.
    Br J Haematol. 2019 Jun 10. doi: 10.1111/bjh.16014.
    PubMed     Abstract available


  110. SPURGEON SE, Sharma K, Claxton DF, Ehmann C, et al
    Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
    Br J Haematol. 2019 Jun 9. doi: 10.1111/bjh.16008.
    PubMed     Abstract available


  111. CASULO C
    How I manage patients with follicular lymphoma.
    Br J Haematol. 2019 Jun 7. doi: 10.1111/bjh.16011.
    PubMed     Abstract available


  112. CHEN Z, Liu W, Zhao S
    Systemic EBV-positive T-cell lymphoma of childhood mimicking anaplastic large cell lymphoma.
    Br J Haematol. 2019;185:1016.
    PubMed    


    May 2019
  113. WANG Y, Maurer MJ, Larson MC, Allmer C, et al
    Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma.
    Br J Haematol. 2019 May 28. doi: 10.1111/bjh.15997.
    PubMed     Abstract available


  114. FARRUGIA D, Grech M, Camilleri D
    Mantle cell lymphoma with lymphocyte aggregates in peripheral blood.
    Br J Haematol. 2019 May 24. doi: 10.1111/bjh.15976.
    PubMed    


  115. KHOGEER H, Rahman H, Jain N, Angelova EA, et al
    Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy.
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15960.
    PubMed     Abstract available


  116. CAIRO MS
    Rituximab in the treatment of childhood mature B-cell lymphoma: "Where do we go from here".
    Br J Haematol. 2019 May 22. doi: 10.1111/bjh.15940.
    PubMed    


  117. TOYODA K, Tsukasaki K, Machida R, Kadota T, et al
    Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801.
    Br J Haematol. 2019 May 16. doi: 10.1111/bjh.15950.
    PubMed     Abstract available


  118. NIJDAM A, Dekker N, Aleman BMP, van 't Veer MB, et al
    Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma.
    Br J Haematol. 2019 May 15. doi: 10.1111/bjh.15936.
    PubMed    


  119. MASCHAN A, Myakova N, Aleinikova O, Abugova Y, et al
    Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M.
    Br J Haematol. 2019 May 9. doi: 10.1111/bjh.15944.
    PubMed     Abstract available


  120. GEER M, Roberts E, Shango M, Till BG, et al
    Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
    Br J Haematol. 2019 May 1. doi: 10.1111/bjh.15923.
    PubMed     Abstract available


    April 2019
  121. BURKART M, Schieber M, Basu S, Shah P, et al
    Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.
    Br J Haematol. 2019 Apr 2. doi: 10.1111/bjh.15889.
    PubMed     Abstract available


  122. NAKASONE H, Tabuchi K, Uchida N, Ohno Y, et al
    Which is more important for the selection of cord blood units for haematopoietic cell transplantation: the number of CD34-positive cells or total nucleated cells?
    Br J Haematol. 2019;185:166-169.
    PubMed    


    March 2019
  123. GHOSH N, Sanikommu S, Robinson M, Trivedi J, et al
    Curative potential of chemoimmunotherapy in diffuse large B cell lymphoma with hepatic and/or renal dysfunction.
    Br J Haematol. 2019 Mar 28. doi: 10.1111/bjh.15897.
    PubMed    


  124. BECNEL MR, Nastoupil LJ, Samaniego F, Davis RE, et al
    Lenalidomide plus rituximab (R(2) ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
    Br J Haematol. 2019 Mar 28. doi: 10.1111/bjh.15843.
    PubMed     Abstract available


  125. LIU F, Kang L, Wang Y
    Cutaneous flushing associated with Hodgkin lymphoma.
    Br J Haematol. 2019 Mar 24. doi: 10.1111/bjh.15873.
    PubMed    


  126. HAPGOOD G, Ben-Neriah S, Mottok A, Lee DG, et al
    Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma.
    Br J Haematol. 2019 Mar 14. doi: 10.1111/bjh.15860.
    PubMed    


  127. PAVLOVSKY A, Fernandez I, Kurgansky N, Prates V, et al
    PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
    Br J Haematol. 2019 Mar 12. doi: 10.1111/bjh.15838.
    PubMed     Abstract available


  128. CHEN L, Li S, Wang M, Li Y, et al
    Expansion deficiency of CAR-T cells in patients with lymphoma and resolution by T cell purification.
    Br J Haematol. 2019 Mar 4. doi: 10.1111/bjh.15822.
    PubMed    


  129. SORGE C, Costa LJ, Taub JW, S Cairo M, et al
    Incidence and outcomes of rare paediatric non-hodgkin lymphomas.
    Br J Haematol. 2019;184:864-867.
    PubMed    


    February 2019
  130. KHASHAB T, Hagemeister F, Romaguera JE, Fanale MA, et al
    Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 28. doi: 10.1111/bjh.15814.
    PubMed     Abstract available


  131. BURKHARDT B, Hermiston ML
    Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities.
    Br J Haematol. 2019 Feb 27. doi: 10.1111/bjh.15793.
    PubMed     Abstract available


  132. MAGNANO L, Alonso-Alvarez S, Alcoceba M, Rivas-Delgado A, et al
    Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population.
    Br J Haematol. 2019 Feb 22. doi: 10.1111/bjh.15805.
    PubMed     Abstract available


  133. RUSCONI C, Anastasia A, Chiarenza A, Marcheselli L, et al
    Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2019 Feb 21. doi: 10.1111/bjh.15816.
    PubMed     Abstract available


  134. IMATAKI O, Uemura M, Kadowaki N
    Lethal cardiac damage resulting from eosinophilia caused by anaplastic large cell lymphoma.
    Br J Haematol. 2019 Feb 21. doi: 10.1111/bjh.15809.
    PubMed    


  135. MUNDT F, Merrien M, Nygren L, Sutton LA, et al
    Expression of GNAZ, encoding the Galphaz protein, predicts survival in mantle cell lymphoma.
    Br J Haematol. 2019 Feb 20. doi: 10.1111/bjh.15810.
    PubMed     Abstract available


  136. MIYAMURA T, Moritake H, Nakayama H, Tanaka S, et al
    Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15799.
    PubMed     Abstract available


  137. GALARDY PJ, Bedekovics T, Macintyre E, Miles RR, et al
    Lymphoma diagnostics: getting more from less.
    Br J Haematol. 2019 Feb 19. doi: 10.1111/bjh.15788.
    PubMed     Abstract available


  138. O'REILLY MA, Govender D, Kirkwood AA, Vora A, et al
    The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15798.
    PubMed    


  139. ROMANO A, Parrinello NL, Chiarenza A, Motta G, et al
    Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.
    Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801.
    PubMed     Abstract available


  140. CHIU H, Trisal P, Bjorklund C, Carrancio S, et al
    Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma.
    Br J Haematol. 2019 Feb 14. doi: 10.1111/bjh.15797.
    PubMed     Abstract available


  141. LEES C, Keane C, Gandhi MK, Gunawardana J, et al
    Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions.
    Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15778.
    PubMed     Abstract available


  142. CHANTADA G, Lam CG, Howard SC
    Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment.
    Br J Haematol. 2019 Feb 10. doi: 10.1111/bjh.15785.
    PubMed     Abstract available


  143. CAIRO MS, Beishuizen A
    Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15764.
    PubMed     Abstract available


  144. ZANELLI M, Zizzo M, De Marco L, Bisagni A, et al
    Fibrin-associated diffuse large B-cell lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15786.
    PubMed    


  145. METZGER ML, Mauz-Korholz C
    Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 6. doi: 10.1111/bjh.15789.
    PubMed     Abstract available


  146. ROSENBAUM CA, Jung SH, Pitcher B, Bartlett NL, et al
    Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
    Br J Haematol. 2019 Feb 5. doi: 10.1111/bjh.15768.
    PubMed     Abstract available


  147. VU K, Mannis G, Hwang J, Geng H, et al
    Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15787.
    PubMed    


  148. EHRHARDT MJ, Hochberg J, Bjornard KL, Brinkman TM, et al
    Long-term survivors of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Feb 3. doi: 10.1111/bjh.15775.
    PubMed     Abstract available


  149. ROISMAN A, Castellano G, Navarro A, Gonzalez-Farre B, et al
    Differential expression of long non-coding RNAs are related to proliferation and histological diversity in follicular lymphomas.
    Br J Haematol. 2019;184:373-383.
    PubMed     Abstract available


  150. LAPA C, Luckerath K, Kircher S, Hanscheid H, et al
    Potential influence of concomitant chemotherapy on CXCR4 expression in receptor directed endoradiotherapy.
    Br J Haematol. 2019;184:440-443.
    PubMed    


  151. RAIMBAULT A, Machherndl-Spandl S, Itzykson R, Clauser S, et al
    CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.
    Br J Haematol. 2019;184:625-633.
    PubMed     Abstract available


  152. ADAMS HJA, Kwee TC
    Assessing complete remission status in incurable follicular lymphomas, to what purpose?
    Br J Haematol. 2019;184:467-469.
    PubMed    


    January 2019
  153. DANIEL V, Delamain MT, Murbach BA, de Souza CA, et al
    Role for DNA base-excision repair gene variants in the prognosis of Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 31. doi: 10.1111/bjh.15779.
    PubMed    


  154. BARTH MJ, Minard-Colin V
    Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 30. doi: 10.1111/bjh.15783.
    PubMed     Abstract available


  155. PACZKOWSKA J, Soloch N, Bodnar M, Kiwerska K, et al
    Expression of ELF1, a lymphoid ETS domain-containing transcription factor, is recurrently lost in classical Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 25. doi: 10.1111/bjh.15757.
    PubMed     Abstract available


  156. CANNATA-ORTIZ J, Nicolas C, Garcia-Noblejas A, Requena MJ, et al
    Rituximab, interferon-alfa-2b and dose dense CVP is highly efficient in patients with FLIPI >/= 2 follicular lymphoma. Final results of the LNH-PRO-05 study.
    Br J Haematol. 2019 Jan 17. doi: 10.1111/bjh.15760.
    PubMed    


  157. BATALLER A, Combalia A, Garcia-Herrera A, Estrach T, et al
    Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15744.
    PubMed    


  158. CHU Y, Gardenswartz A, Termuhlen AM, Cairo MS, et al
    Advances in cellular and humoral immunotherapy - implications for the treatment of poor risk childhood, adolescent, and young adult B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2019 Jan 6. doi: 10.1111/bjh.15753.
    PubMed     Abstract available


  159. CWYNARSKI K, Marzolini MAV, Barrington SF, Follows G, et al
    The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2019 Jan 4. doi: 10.1111/bjh.15731.
    PubMed    


  160. EVENS AM
    Important new developments in Hodgkin Lymphoma.
    Br J Haematol. 2019;184:6.
    PubMed    


  161. DEPAUS J, Delcourt A, Andre M
    Therapeutic recommendations for early stage Hodgkin lymphomas.
    Br J Haematol. 2019;184:9-16.
    PubMed     Abstract available


    December 2018
  162. NAKAYAMA S, Taniguchi T, Tanaka H, Espinoza JL, et al
    Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome.
    Br J Haematol. 2018 Dec 28. doi: 10.1111/bjh.15733.
    PubMed    


  163. BOLL B, Plutschow A, Burkle C, Atta J, et al
    Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
    Br J Haematol. 2018 Dec 28. doi: 10.1111/bjh.15741.
    PubMed     Abstract available


  164. HILL BT, Nastoupil L, Winter AM, Becnel MR, et al
    Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
    Br J Haematol. 2018 Dec 21. doi: 10.1111/bjh.15720.
    PubMed     Abstract available


  165. RULE S, Cook G, Russell NH, Hunter A, et al
    Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
    Br J Haematol. 2018 Dec 17. doi: 10.1111/bjh.15723.
    PubMed     Abstract available


  166. REDONDO AM, Valcarcel D, Gonzalez-Rodriguez AP, Suarez-Lledo M, et al
    Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
    Br J Haematol. 2018 Dec 12. doi: 10.1111/bjh.15713.
    PubMed     Abstract available


  167. LIN RJ, Ho C, Hilden PD, Barker JN, et al
    Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
    Br J Haematol. 2018 Dec 11. doi: 10.1111/bjh.15721.
    PubMed     Abstract available


  168. VON KEUDELL G, Younes A
    Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
    Br J Haematol. 2018 Dec 11. doi: 10.1111/bjh.15695.
    PubMed     Abstract available


  169. UMAKANTHAN JM, Iqbal J, Batlevi CL, Bouska A, et al
    Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.
    Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15702.
    PubMed     Abstract available


  170. FRIEDRICHS B, Nickelsen M, Ziepert M, Altmann B, et al
    Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.
    Br J Haematol. 2018 Dec 5. doi: 10.1111/bjh.15710.
    PubMed     Abstract available


  171. RIVAS-DELGADO A, Magnano L, Moreno-Velazquez M, Garcia O, et al
    Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era.
    Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15708.
    PubMed     Abstract available


  172. HOHLOCH K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, et al
    Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.
    Br J Haematol. 2018 Dec 4. doi: 10.1111/bjh.15712.
    PubMed     Abstract available


  173. GHOLIHA AR, Hollander P, Hedstrom G, Sundstrom C, et al
    High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms.
    Br J Haematol. 2018 Dec 2. doi: 10.1111/bjh.15703.
    PubMed     Abstract available


    November 2018
  174. LUO J, Wang SS, Lu Y, Sullivan-Halley J, et al
    Pregnancy-related factors and risk of B-cell non-Hodgkin lymphoma among women in Los Angeles.
    Br J Haematol. 2018 Nov 29. doi: 10.1111/bjh.15699.
    PubMed    


  175. SPINNER MA, Varma G, Advani RH
    Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15616.
    PubMed     Abstract available


  176. TANIGUCHI T, Nakayama S, Morita Y, Rai S, et al
    Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion.
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15689.
    PubMed    


  177. VISSER L
    Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
    Br J Haematol. 2018 Nov 28. doi: 10.1111/bjh.15704.
    PubMed    


  178. MCCULLOCH R, Smith A, Crosbie N, Patmore R, et al
    Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma.
    Br J Haematol. 2018 Nov 26. doi: 10.1111/bjh.15696.
    PubMed    


  179. FOX CP, Phillips EH, Smith J, Linton K, et al
    Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.
    Br J Haematol. 2018 Nov 23. doi: 10.1111/bjh.15661.
    PubMed    


  180. BRIERLEY CK, Jones FM, Hanlon K, Peniket AJ, et al
    Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Br J Haematol. 2018 Nov 22. doi: 10.1111/bjh.15685.
    PubMed     Abstract available


  181. CROMBIE JL, LaCasce AS
    Current considerations in AYA Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 20. doi: 10.1111/bjh.15640.
    PubMed     Abstract available


  182. STENGEL A, Kern W, Meggendorfer M, Haferlach T, et al
    Detailed molecular analysis and evaluation of prognosis in cases with high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
    Br J Haematol. 2018 Nov 20. doi: 10.1111/bjh.15653.
    PubMed    


  183. PAINSCHAB MS, Kasonkanji E, Zuze T, Kaimila B, et al
    Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
    Br J Haematol. 2018 Nov 18. doi: 10.1111/bjh.15625.
    PubMed     Abstract available


  184. ADAMS HJA, Kwee TC
    Interim FDG-PET does not predict outcome in advanced-stage Hodgkin lymphoma patients treated with BEACOPP.
    Br J Haematol. 2018 Nov 14. doi: 10.1111/bjh.15602.
    PubMed    


  185. GALATI D, Zanotta S, Corazzelli G, Bruzzese D, et al
    Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 13. doi: 10.1111/bjh.15676.
    PubMed     Abstract available


  186. CIRILLO M, Reinke S, Klapper W, Borchmann S, et al
    The translational science of hodgkin lymphoma.
    Br J Haematol. 2018 Nov 12. doi: 10.1111/bjh.15658.
    PubMed     Abstract available


  187. MITSUI T, Yokohama A, Koiso H, Saito A, et al
    Prognostic impact of trisomy 21 in follicular lymphoma.
    Br J Haematol. 2018 Nov 12. doi: 10.1111/bjh.15664.
    PubMed     Abstract available


  188. LONGLEY J, Johnson PWM
    Current treatment paradigms for advanced stage Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15622.
    PubMed     Abstract available


  189. HIEMCKE-JIWA LS, Leguit RJ, Snijders TJ, Bromberg JEC, et al
    MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15674.
    PubMed    


  190. PAINTER D, Barrans S, Lacy S, Smith A, et al
    Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15619.
    PubMed    


  191. HIEMCKE-JIWA LS, Leguit RJ, Jiwa NM, Huibers MMH, et al
    CXCR4 mutations in lymphoplasmacytic lymphoma lead to altered CXCR4 expression.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15670.
    PubMed    


  192. IANNITTO E, Bellei M, Amorim S, Ferreri AJM, et al
    Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15641.
    PubMed     Abstract available


  193. VALCHEV G, Alaikov T, Shivarov V
    Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15662.
    PubMed    


  194. BOLL B, Gorgen H
    The treatment of older Hodgkin lymphoma patients.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15652.
    PubMed     Abstract available


  195. VISCO C, Tisi MC, Evangelista A, Di Rocco A, et al
    Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15643.
    PubMed    


  196. MAYBURY B, Kimpton G, Otton S
    A retrospective multicentre study of COCKLE, an oral chemotherapy regimen, as palliative treatment for high grade lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15637.
    PubMed    


  197. BROCCOLI A, Zinzani PL
    The role of transplantation in Hodgkin lymphoma.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15639.
    PubMed     Abstract available


  198. WANG HW, Balakrishna JP, Pittaluga S, Jaffe ES, et al
    Diagnosis of Hodgkin lymphoma in the modern era.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15614.
    PubMed     Abstract available


  199. BAECH J, Hansen SM, Lund PE, Soegaard P, et al
    Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
    Br J Haematol. 2018 Nov 8. doi: 10.1111/bjh.15603.
    PubMed     Abstract available


  200. BUDDE LE, Wu D, Martin DB, Philip M, et al
    Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
    Br J Haematol. 2018;183:601-607.
    PubMed     Abstract available


    October 2018
  201. TALAULIKAR D, Biscoe A, Lim JH, Gibson J, et al
    Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenstrom Macroglobulinaemia reveals different patterns of clonal evolution.
    Br J Haematol. 2018 Oct 18. doi: 10.1111/bjh.15610.
    PubMed    


    September 2018
  202. BROCKELMANN PJ, McMullen S, Wilson JB, Mueller K, et al
    Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
    Br J Haematol. 2018 Sep 21. doi: 10.1111/bjh.15566.
    PubMed     Abstract available


  203. CENCINI E, Sicuranza A, Fabbri A, Ferrigno I, et al
    Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab.
    Br J Haematol. 2018 Sep 11. doi: 10.1111/bjh.15582.
    PubMed     Abstract available


  204. FAULK KE, Sopfe JM, Campbell K, Liptzin DR, et al
    Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15586.
    PubMed     Abstract available


  205. JIANG C, Bi C, Jiang X, Tian T, et al
    The miR-17~92 cluster activates mTORC1 in mantle cell lymphoma by targeting multiple regulators in the STK11/AMPK/TSC/mTOR pathway.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15591.
    PubMed    


  206. BRANDEFORS L, Melin B, Lindh J, Lundqvist K, et al
    Prognostic factors and primary treatment for Waldenstrom macroglobulinemia - a Swedish Lymphoma Registry study.
    Br J Haematol. 2018 Sep 10. doi: 10.1111/bjh.15558.
    PubMed     Abstract available


  207. ANDORSKY DJ, Kolibaba KS, Assouline S, Forero-Torres A, et al
    An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Br J Haematol. 2018 Sep 5. doi: 10.1111/bjh.15552.
    PubMed     Abstract available


  208. JAIN P, Kanagal-Shamanna R, Zhang S, Ahmed M, et al
    Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
    Br J Haematol. 2018 Sep 2. doi: 10.1111/bjh.15567.
    PubMed     Abstract available



  209. Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma Abstracts, 26-29 September 2018, De Doelen International Congress Centre, Rotterdam, Netherlands.
    Br J Haematol. 2018;182 Suppl 1:5-109.
    PubMed    


    August 2018
  210. WALEWSKI J, Hellmann A, Siritanaratkul N, Ozsan GH, et al
    Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
    Br J Haematol. 2018 Aug 30. doi: 10.1111/bjh.15539.
    PubMed     Abstract available


  211. SETO AG, Beatty X, Lynch JM, Hermreck M, et al
    Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.
    Br J Haematol. 2018 Aug 20. doi: 10.1111/bjh.15547.
    PubMed     Abstract available


  212. HWANG AE, Marshall V, Conti DV, Nathwani BN, et al
    Epstein-Barr virus load is higher in long-term Hodgkin lymphoma survivors compared to their unaffected twins and unrelated controls.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15522.
    PubMed    


  213. GYAN E, Sonet A, Brice P, Anglaret B, et al
    Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15513.
    PubMed     Abstract available


  214. FRAZER JK, Li KJ, Galardy PJ, Perkins SL, et al
    Excellent outcomes in children and adolescents with CNS(+) burkitt lymphoma or other mature B-NHL using only intrathecal and systemic chemoimmunotherapy: results from FAB/LMB96 and COG ANHL01P1.
    Br J Haematol. 2018 Aug 16. doi: 10.1111/bjh.15520.
    PubMed    


  215. RAUERT-WUNDERLICH H, Mottok A, Scott DW, Rimsza LM, et al
    Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network.
    Br J Haematol. 2018 Aug 10. doi: 10.1111/bjh.15519.
    PubMed     Abstract available


  216. MURBACH BA, Delamain MT, Daniel V, de Souza CA, et al
    Association between polymorphisms in angiogenesis-related genes and the prognosis of classical Hodgkin lymphoma.
    Br J Haematol. 2018 Aug 6. doi: 10.1111/bjh.15512.
    PubMed    


  217. SU C, Bai HX, Xiao R
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some of the apparent ethnic dispa
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15526.
    PubMed    


  218. LO BELLO G, Naresh KN
    HTLV-1 status should be recorded in cases of T cell lymphomas/lymphoproliferative disorders - cases of adult T cell leukaemia lymphoma masquerading as other T cell lymphomas/lymphoproliferative disorders could explain some apparent ethnic disparities.
    Br J Haematol. 2018 Aug 3. doi: 10.1111/bjh.15527.
    PubMed    


    July 2018
  219. BIGENWALD C, Fardet L, Coppo P, Meignin V, et al
    A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis.
    Br J Haematol. 2018 Jul 24. doi: 10.1111/bjh.15506.
    PubMed     Abstract available


  220. CAIRO M, Auperin A, Perkins SL, Pinkerton R, et al
    Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15491.
    PubMed     Abstract available


  221. AVIVI I, Arcaini L, Ferretti VV, Boumendil A, et al
    High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15454.
    PubMed     Abstract available


  222. KHAN UT, Racu-Amoasii I, Arumainathan A, Meswani U, et al
    Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis.
    Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15489.
    PubMed    


  223. TRACHTENBERG E, Mashiach T, Ben Hayun R, Tadmor T, et al
    Cognitive impairment in hodgkin lymphoma survivors.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15448.
    PubMed     Abstract available


  224. NITTA H, Gotoh A, Tanaka M, Sekiguchi Y, et al
    Pleural effusion at diagnosis predicts extremely poor outcomes in patients with diffuse large B-cell lymphoma harbouring MYC rearrangement.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15431.
    PubMed    


  225. AILAWADHI S, Dholaria BR, Khurana S, Sher T, et al
    Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15458.
    PubMed    


  226. EL-SHARKAWI D, Ng CH, Payne EM, Yong KL, et al
    Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15457.
    PubMed    


  227. MONTALBAN C, Diaz-Lopez A, Martin A, Baile M, et al
    Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15446.
    PubMed     Abstract available


  228. CHIHARA D, Oki Y, Fanale MA, Westin JR, et al
    Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
    Br J Haematol. 2018 Jul 5. doi: 10.1111/bjh.15444.
    PubMed    


    June 2018
  229. AZOULAY D, Nasser R, Sharon R, Simanovich L, et al
    Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine-induced peripheral neuropathy in patients with lymphoma.
    Br J Haematol. 2018 Jun 25. doi: 10.1111/bjh.15428.
    PubMed    


  230. DERENZINI E, Agostinelli C, Rossi A, Rossi M, et al
    Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma.
    Br J Haematol. 2018 Jun 17. doi: 10.1111/bjh.15442.
    PubMed    


  231. MCKAY P, Leach M, Jackson B, Robinson S, et al
    A British Society for haematology good practice paper on the diagnosis and investigation of patients with mantle cell lymphoma.
    Br J Haematol. 2018 Jun 8. doi: 10.1111/bjh.15281.
    PubMed    


  232. BLACKLAWS J, Seamone ME, Gupta RR
    Spectral domain optical coherence tomography interpretation.
    Br J Haematol. 2018;181:710.
    PubMed    


  233. FEND F, Coupland S
    Spectral domain optical coherence tomography interpretation - Response to Blacklaws et al.
    Br J Haematol. 2018;181:711.
    PubMed    


  234. FELDMAN AL, Flowers CR
    Ethnic disparity in primary cutaneous CD30(+) T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US National Cancer database.
    Br J Haematol. 2018;181:721-722.
    PubMed    


    May 2018
  235. KOMMALAPATI A, Tella SH, Go RS, Nowakowski GS, et al
    T cell/histiocyte-rich large B cell lymphoma: incidence, demographic disparities, and long-term outcomes.
    Br J Haematol. 2018 May 30. doi: 10.1111/bjh.15391.
    PubMed    


  236. VAN WESTRHENEN A, Smidt LCA, Seute T, Nierkens S, et al
    Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15410.
    PubMed     Abstract available


  237. KURT H, Medeiros LJ, Khoury JD, Schlette EJ, et al
    Epstein-Barr virus-positive follicular lymphoma.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15419.
    PubMed    


  238. FAMA A, Xiang J, Link BK, Allmer C, et al
    Human Pegivirus infection and lymphoma risk and prognosis: a North American study.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15416.
    PubMed     Abstract available


  239. GISSELBRECHT C, Van Den Neste E
    How I manage patients with relapsed/refractory diffuse large B cell lymphoma.
    Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15412.
    PubMed     Abstract available


  240. WITTE H, Biersack H, Kopelke S, Rades D, et al
    The Glasgow prognostic score at diagnosis is an independent predictor of survival in advanced stage classical Hodgkin lymphoma.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15198.
    PubMed    


  241. SHI J, Bodo J, Zhao X, Durkin L, et al
    SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target.
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15393.
    PubMed    


  242. MARALDO MV, Illidge TM
    How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15256.
    PubMed    


  243. JAIN P, Romaguera J, Srour SA, Lee HJ, et al
    Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15411.
    PubMed     Abstract available


  244. MCKAY P, Leach M, Jackson B, Robinson S, et al
    Guideline for the management of mantle cell lymphoma.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15283.
    PubMed    


  245. BRAM EDNERSSON S, Stenson M, Stern M, Enblad G, et al
    Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15259.
    PubMed     Abstract available


  246. MANWANI R, Wrench D, Wechalekar A, Lachmann H, et al
    Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma.
    Br J Haematol. 2018 May 16. doi: 10.1111/bjh.15269.
    PubMed    


  247. VERA-LOZADA G, Barros MHM, Alves P, Segges P, et al
    EOMES/TBET and soluble CTLA4/full length CTLA4 expression ratios impact on the therapeutic response in patients with classical Hodgkin lymphoma.
    Br J Haematol. 2018 May 9. doi: 10.1111/bjh.15253.
    PubMed    


  248. ZHU KY, Song KW, Connors JM, Leitch H, et al
    Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Br J Haematol. 2018 May 9. doi: 10.1111/bjh.15262.
    PubMed     Abstract available


  249. ROMAGUERA JE, Lee HJ, Tarapore R, Prabhu V, et al
    Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment.
    Br J Haematol. 2018 May 8. doi: 10.1111/bjh.15271.
    PubMed    


  250. MCMASTER ML, Sun C, Landi MT, Savage SA, et al
    Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma.
    Br J Haematol. 2018;181:372-377.
    PubMed     Abstract available


  251. OLSZEWSKI AJ, Ollila T, Reagan JL
    Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.
    Br J Haematol. 2018;181:495-504.
    PubMed     Abstract available


  252. LI Z, Lu L, Zhou Z, Xue W, et al
    Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2018;181:406-410.
    PubMed    


  253. BOND J, Touzart A, Nadal N, Trinquand A, et al
    Early thymic precursor-like lymphomatous presentation of the ETV6-NCOA2 translocation.
    Br J Haematol. 2018;181:392-394.
    PubMed    


    April 2018
  254. PARSONS SK, Kelly MJ, Cohen JT, Castellino SM, et al
    Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes.
    Br J Haematol. 2018 Apr 29. doi: 10.1111/bjh.15255.
    PubMed     Abstract available


  255. CHIN CK, Tsang E, Mediwake H, Khair W, et al
    Frequency of bowel perforation and impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15173.
    PubMed    


  256. KARIMI P, Birmann BM, Anderson LA, McShane CM, et al
    Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15229.
    PubMed     Abstract available


  257. FRIDTHJOF KS, Kampmann P, Dunweber A, Gorlov JS, et al
    Systematic patient involvement for homebased outpatient administration of complex chemotherapy in acute leukemia and lymphoma.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15249.
    PubMed     Abstract available


  258. MALIK B, Taylor GP
    Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.
    Br J Haematol. 2018 Apr 20. doi: 10.1111/bjh.15234.
    PubMed    


  259. FEDERICO M, Bellei M, Marcheselli L, Schwartz M, et al
    Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
    Br J Haematol. 2018 Apr 19. doi: 10.1111/bjh.15258.
    PubMed     Abstract available


  260. DEAU B, Amorim S, Perrot A, Quittet P, et al
    Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15184.
    PubMed     Abstract available


  261. SPRIANO F, Chung EY, Panini N, Cascione L, et al
    Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15212.
    PubMed    


  262. LINK BK, Day BM, Zhou X, Zelenetz AD, et al
    Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15149.
    PubMed    


  263. CITRIN R, Getz KD, Li Y, Huang YS, et al
    The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Br J Haematol. 2018 Apr 2. doi: 10.1111/bjh.15159.
    PubMed    


  264. SINGAVI AK, Shah NN
    Graft-versus-host disease-associated hepatic portal venous gas.
    Br J Haematol. 2018;181:9.
    PubMed    


  265. GALANINA N, Smith SM, Liao C, Petrich A, et al
    University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
    Br J Haematol. 2018;181:264-267.
    PubMed    


  266. GIFFORD G, Gabrielli S, Gill A, Greenwood M, et al
    Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
    Br J Haematol. 2018;181:272-275.
    PubMed    


  267. MESGUICH C, Cazeau AL, Bouabdallah K, Hindie E, et al
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
    Br J Haematol. 2018;181:124-125.
    PubMed    


  268. ADAMS HJA, Kwee TC
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
    Br J Haematol. 2018;181:122-123.
    PubMed    


  269. RESTELLI V, Vagni M, Arribas AJ, Bertoni F, et al
    Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
    Br J Haematol. 2018;181:129-133.
    PubMed    


    March 2018
  270. NGUYEN KA, Su C, Bai HX, Zhang Z, et al
    Disease site as a determinant of survival outcome in patients with systemic anaplastic lymphoma kinase positive anaplastic large cell lymphoma with extranodal involvement: an analysis of 1306 cases from the US National Cancer Database.
    Br J Haematol. 2018 Mar 30. doi: 10.1111/bjh.15145.
    PubMed     Abstract available


  271. SMITH A, Roman E, Appleton S, Howell D, et al
    Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN).
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15170.
    PubMed     Abstract available


  272. MINSON A, Douglas G, Bilmon I, Grigg A, et al
    Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15186.
    PubMed    


  273. MELANI C, Wilson WH, Roschewski M
    What is the standard of care for primary mediastinal b-cell lymphoma; R-CHOP or DA-EPOCH-R?
    Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15185.
    PubMed    


  274. SHAH NN, Fenske TS, Hamadani M, Svoboda J, et al
    What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15183.
    PubMed    


  275. LEE HJ, Badillo M, Romaguera J, Wang M, et al
    A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15107.
    PubMed    


  276. VAN TIENEN C, Visser O, Lugtenburg P, Taylor G, et al
    Overrepresentation of patients from HTLV-1 endemic countries among T cell Non-Hodgkin lymphomas in the Netherlands: an indication of under-diagnosis of Adult T cell leukaemia/lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15160.
    PubMed    


  277. CASTILLO JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, et al
    Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.
    Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15156.
    PubMed    


  278. LAVOLE J, Le Goff M, Oudjit A, Sogni P, et al
    Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
    Br J Haematol. 2018;180:629.
    PubMed    


  279. KALAC M, Lue JK, Lichtenstein E, Turenne I, et al
    Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
    Br J Haematol. 2018;180:757-760.
    PubMed    


  280. NISHINO M, Ramaiya NH, Hatabu H, Hodi FS, et al
    PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
    Br J Haematol. 2018;180:752-755.
    PubMed    


  281. DI NAPOLI A, Jain P, Duranti E, Margolskee E, et al
    Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.
    Br J Haematol. 2018;180:741-744.
    PubMed    


  282. STASILOJC G, Felberg A, Okroj M
    Parameters critical for the effector mechanism of anti-CD20 antibodies revisited.
    Br J Haematol. 2018;180:777-779.
    PubMed    


  283. MENTER T, Medani H, Olavarria E, Kanfer E, et al
    Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018;180:904-908.
    PubMed    


  284. ALLEN PB, Pavone ME, Smith KN, Kazer RR, et al
    The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience.
    Br J Haematol. 2018;180:901-904.
    PubMed    


    February 2018
  285. BELTRAN BE, Castro D, De La Cruz-Vargas JA, Cotrina E, et al
    The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma.
    Br J Haematol. 2018 Feb 26. doi: 10.1111/bjh.15141.
    PubMed    


  286. KARAM JD, Zerbib Y, Meyer ME, Delette C, et al
    Spontaneous tumour lysis syndrome in a primary adrenal lymphoma.
    Br J Haematol. 2018 Feb 26. doi: 10.1111/bjh.15143.
    PubMed    


  287. VACHHANI P, Neppalli VT, Cancino CJ, Bogner P, et al
    Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.
    Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15154.
    PubMed    


  288. BAZARBACHI A, Boumendil A, Finel H, Mohty M, et al
    Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15152.
    PubMed     Abstract available


  289. HUDSON KE, Rizzieri D, Thomas SM, LeBlanc TW, et al
    Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
    Br J Haematol. 2018 Feb 21. doi: 10.1111/bjh.15138.
    PubMed    


  290. DEMARIA L, Henry J, Seror R, Frenzel L, et al
    Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjogren syndrome (pSS).
    Br J Haematol. 2018 Feb 9. doi: 10.1111/bjh.15120.
    PubMed    


  291. ISHIDA T, Jo T, Takemoto S, Suzushima H, et al
    Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15123.
    PubMed    


  292. BOUTAULT R, Le Glaunec J, Debord C, Robillard N, et al
    Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping.
    Br J Haematol. 2018 Feb 1. doi: 10.1111/bjh.14968.
    PubMed    


  293. FOX TA, Jager R, Ardeshna KM
    Cerebrospinal fluid leak after bone marrow biopsy.
    Br J Haematol. 2018;180:319.
    PubMed    


    January 2018
  294. JIANG H, Lwin T, Zhao X, Ren Y, et al
    Venetoclax as a single agent and in combination with PI3K-MTOR1/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma.
    Br J Haematol. 2018 Jan 30. doi: 10.1111/bjh.15079.
    PubMed    


  295. SMYTH L, Buckstein R, Pennell N, Weerasinghe R, et al
    Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-alpha induces prolonged clinical and molecular remissions in patients with follicular lymphoma.
    Br J Haematol. 2018 Jan 30. doi: 10.1111/bjh.15118.
    PubMed    


  296. RUTHERFORD SC, Leonard JP
    Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.
    Br J Haematol. 2018 Jan 29. doi: 10.1111/bjh.15113.
    PubMed    


  297. HERSHKOVITZ-ROKAH O, Pulver D, Lenz G, Shpilberg O, et al
    Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
    Br J Haematol. 2018 Jan 23. doi: 10.1111/bjh.15108.
    PubMed     Abstract available


    December 2017
  298. REDDY JP, Hernandez M, Gunther JR, Dabaja BS, et al
    Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
    Br J Haematol. 2017 Dec 21. doi: 10.1111/bjh.15054.
    PubMed     Abstract available


  299. ROVO A, Kulasekararaj A, Medinger M, Chevallier P, et al
    Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15074.
    PubMed    


  300. ADAMS HJA, Kwee TC
    Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15071.
    PubMed    


  301. MILGROM SA, Pinnix CC, Gunther JR, Fanale M, et al
    Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15072.
    PubMed    


  302. GHIONE P, Cavallo F, Visco C, Chen Z, et al
    A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15057.
    PubMed    


  303. SHAH NN, Szabo A, Huntington SF, Epperla N, et al
    R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
    Br J Haematol. 2017 Dec 19. doi: 10.1111/bjh.15051.
    PubMed     Abstract available


  304. SOLAL-CELIGNY P, Leconte P, Bardet A, Hernandez J, et al
    A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Br J Haematol. 2017 Dec 12. doi: 10.1111/bjh.15023.
    PubMed     Abstract available


  305. SCHICK M, Habringer S, Nilsson JA, Keller U, et al
    Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
    Br J Haematol. 2017;179:724-738.
    PubMed     Abstract available


  306. RADESKI D, Montanari F, Alobeid B, O'Connor OA, et al
    Post-transplant lymphoproliferative disorder: a heterogeneous conundrum - response to Weisenburger DD & Gross TG.
    Br J Haematol. 2017;179:856-857.
    PubMed    


  307. WEISENBURGER DD, Gross TG
    Post-transplant lymphoproliferative disorder: a heterogeneous conundrum.
    Br J Haematol. 2017;179:854-856.
    PubMed    


    November 2017
  308. FLINN IW, Thompson DS, Boccia RV, Miletello G, et al
    Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15044.
    PubMed     Abstract available


  309. ARCAINI L, Lamy T, Walewski J, Belada D, et al
    Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15025.
    PubMed     Abstract available


  310. HOHLOCH K, Altmann B, Pfreundschuh M, Loeffler M, et al
    Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15029.
    PubMed     Abstract available


  311. ZAMO A, Pischimarov J, Horn H, Ott G, et al
    The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15041.
    PubMed     Abstract available


  312. FRAME IJ, Coberly J, Fuda FS, Chen M, et al
    Erythrophagocytosis by T-cell lymphoma cells in a patient with hereditary spherocytosis post-splenectomy.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15028.
    PubMed    


  313. KARAKAWA A, Taoka K, Kaburaki T, Tanaka R, et al
    Clinical features and outcomes of secondary intraocular lymphoma.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15005.
    PubMed    


  314. LIN RJ, Ma H, Guo R, Troxel AB, et al
    Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15027.
    PubMed     Abstract available


  315. PFREUNDSCHUH M, Murawski N, Zeynalova S, Ziepert M, et al
    Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Br J Haematol. 2017;179:410-420.
    PubMed     Abstract available


  316. MENTER T, Medani H, Ahmad R, Flora R, et al
    MYC and BCL2 evaluation in routine diagnostics of aggressive B-cell lymphomas - presentation of a work-flow and the experience with 248 cases.
    Br J Haematol. 2017;179:681-684.
    PubMed    


    October 2017
  317. GIULINO-ROTH L, O'Donohue T, Chen Z, Bartlett NL, et al
    Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Br J Haematol. 2017 Oct 29. doi: 10.1111/bjh.14951.
    PubMed     Abstract available


  318. PRETTYJOHNS M, Hoskin P, McNamara C, Linch D, et al
    The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14990.
    PubMed     Abstract available


  319. QIU Y, Li Z, Pouzoulet F, Vishnu P, et al
    Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.15009.
    PubMed    


  320. CHASE ML, Armand P
    Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14996.
    PubMed     Abstract available


  321. MANSO R, Sanchez-Beato M, Gonzalez-Rincon J, Gomez S, et al
    Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14984.
    PubMed    


  322. GAUDIO E, Paduano F, Pinton S, D'Agostino S, et al
    TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14989.
    PubMed    


  323. CORNISH N, Maybury B, Otton S
    A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14959.
    PubMed    


  324. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Abstract available


    September 2017
  325. THANARAJASINGAM G, Maurer MJ, Farooq U, Johnston PB, et al
    Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
    Br J Haematol. 2017 Sep 29. doi: 10.1111/bjh.14922.
    PubMed    


  326. ADAMS HJA, Kwee TC
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2017 Sep 14. doi: 10.1111/bjh.14906.
    PubMed    


  327. YAMANI F, Chen W
    Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge.
    Br J Haematol. 2017 Sep 7. doi: 10.1111/bjh.14904.
    PubMed    


  328. PROCHAZKA KT, Posch F, Deutsch A, Beham-Schmid C, et al
    Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 Sep 6. doi: 10.1111/bjh.14912.
    PubMed    


  329. OTT G
    Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Br J Haematol. 2017;178:871-887.
    PubMed     Abstract available


  330. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Abstract available


  331. MADDY L, Campbell PJ, Kipp D, Rose HL, et al
    Richter syndrome presenting as Sister Mary Joseph umbilical nodule.
    Br J Haematol. 2017;178:659.
    PubMed    


    August 2017
  332. EYRE TA, Phillips EH, Linton KM, Kassam S, et al
    Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14898.
    PubMed     Abstract available


  333. MUSSOLIN L, Pillon M, Zimmermann M, Carraro E, et al
    Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14864.
    PubMed    


  334. DANN EJ, Paltiel O
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14905.
    PubMed    


  335. RULE S, Dreyling M, Goy A, Hess G, et al
    Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14870.
    PubMed     Abstract available


  336. MILGROM SA, Pinnix CC, Chuang H, Oki Y, et al
    Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14902.
    PubMed     Abstract available


  337. COX MC, Di Napoli A, Fabbri A, Cencini E, et al
    The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Aug 17. doi: 10.1111/bjh.14873.
    PubMed    


  338. ALONSO-ALVAREZ S, Magnano L, Alcoceba M, Andrade-Campos M, et al
    Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Br J Haematol. 2017 Aug 7. doi: 10.1111/bjh.14831.
    PubMed     Abstract available


  339. KANATE AS, DiGilio A, Ahn KW, Al Malki M, et al
    Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14879.
    PubMed    


  340. JAIN P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, et al
    Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14857.
    PubMed    


  341. HAGNER PR, Chiu H, Ortiz M, Apollonio B, et al
    Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14866.
    PubMed     Abstract available


  342. FERRERI AJM, Cecchetti C, Kiesewetter B, Sassone M, et al
    Clarithromycin as a "repurposing drug" against MALT lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14878.
    PubMed    


  343. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Abstract available


  344. MAKAROVA O, Oschlies I, Muller S, Ruf S, et al
    Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14868.
    PubMed    


  345. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Abstract available


  346. SROUR SA, Li S, Popat UR, Qazilbash MH, et al
    A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Br J Haematol. 2017;178:561-570.
    PubMed     Abstract available


  347. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Abstract available


    July 2017
  348. SHIVAROV V, Ivanova M
    Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14861.
    PubMed    


  349. CASCIONE L, Rinaldi A, Chiappella A, Kwee I, et al
    Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14817.
    PubMed    


  350. DELLA PEPA R, Picardi M, Giordano C, Zacheo I, et al
    Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14856.
    PubMed    


  351. WESTMORELAND KD, El-Mallawany NK, Kazembe P, Stanley CC, et al
    Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment.
    Br J Haematol. 2017 Jul 17. doi: 10.1111/bjh.14716.
    PubMed    


  352. MANSO R, Martinez-Magunacelaya N, Chamizo C, Rojo F, et al
    Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14824.
    PubMed    


  353. KABURAKI T, Taoka K, Matsuda J, Yamashita H, et al
    Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14848.
    PubMed     Abstract available


  354. TOMITA N
    Histological assessment at follicular lymphoma progression.
    Br J Haematol. 2017 Jul 7. doi: 10.1111/bjh.14834.
    PubMed    


  355. DANG NH, Ogura M, Castaigne S, Fayad LE, et al
    Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14820.
    PubMed    


  356. RUTHERFORD SC, Li V, Ghione P, Chen Z, et al
    Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14839.
    PubMed     Abstract available


  357. MENTER T, Juskevicius D, Alikian M, Steiger J, et al
    Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
    Br J Haematol. 2017;178:48-56.
    PubMed     Abstract available


    June 2017
  358. FAROOQ U, Maurer MJ, Thompson CA, Thanarajasingam G, et al
    Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14813.
    PubMed     Abstract available


  359. BERNASCONI E, Gaudio E, Lejeune P, Tarantelli C, et al
    Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14803.
    PubMed     Abstract available


  360. MODVIG L, Vase M, d'Amore F
    Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14822.
    PubMed     Abstract available


  361. SZCZEPANOWSKI M, Lange J, Kohler CW, Masque-Soler N, et al
    Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14812.
    PubMed     Abstract available


  362. PRATT G, Yap C, Oldreive C, Slade D, et al
    A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793.
    PubMed    


  363. STRUSSMANN T, Fritsch K, Baumgarten A, Fietz T, et al
    Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14802.
    PubMed     Abstract available


  364. LI L, Duan W, Zhang L, Li X, et al
    The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    Br J Haematol. 2017 Jun 9. doi: 10.1111/bjh.14763.
    PubMed     Abstract available


  365. DANN EJ, Bairey O, Bar-Shalom R, Mashiach T, et al
    Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Br J Haematol. 2017 Jun 7. doi: 10.1111/bjh.14734.
    PubMed     Abstract available


    May 2017
  366. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Abstract available


  367. BECH RS, Nielsen KL, Larsen TS, Bentzen HH, et al
    Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
    Br J Haematol. 2017 May 23. doi: 10.1111/bjh.14775.
    PubMed    


  368. FONSECA E SILVA D, Lopes MS, Pedrosa C, Regadas L, et al
    Burkitt lymphoma.
    Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14758.
    PubMed    


  369. SHIMONO J, Miyoshi H, Kiyasu J, Sato K, et al
    Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14736.
    PubMed     Abstract available


  370. LI Y, Wang L, Zhu HY, Liang JH, et al
    Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14735.
    PubMed    


  371. CHASTY B, Patterson M, Murray LJ, Johnson R, et al
    Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14745.
    PubMed    


  372. CERIANI L, Martelli M, Conconi A, Zinzani PL, et al
    Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14728.
    PubMed     Abstract available


  373. CEDERLEUF H, Bjerregard Pedersen M, Jerkeman M, Relander T, et al
    The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Br J Haematol. 2017 May 8. doi: 10.1111/bjh.14740.
    PubMed     Abstract available


  374. LEE S, Day NS, Miles RR, Perkins SL, et al
    Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.
    Br J Haematol. 2017 May 4. doi: 10.1111/bjh.14604.
    PubMed     Abstract available


  375. BOYLE T, Connors JM, Gascoyne RD, Berry BR, et al
    Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14702.
    PubMed     Abstract available


  376. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Abstract available


    April 2017
  377. EPPERLA N, Hamadani M, Fenske TS, Costa LJ, et al
    Incidence and survival trends in mantle cell lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14699.
    PubMed    


  378. BATLEVI CL, Crump M, Andreadis C, Rizzieri D, et al
    A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14698.
    PubMed     Abstract available


  379. HUSSAIN S, Hallam S, Beltran L, Haroon A, et al
    Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14715.
    PubMed    


  380. HUDE I, Sasse S, Brockelmann PJ, von Tresckow B, et al
    Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14705.
    PubMed    


  381. CAVALLI M, De Novi LA, Della Starza I, Cappelli LV, et al
    Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14616.
    PubMed     Abstract available


  382. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Abstract available


  383. TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
    Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
    PubMed    


  384. WANG Z, Cook JR
    PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14670.
    PubMed    


  385. SZYCHOT E, Shankar A, Haider A, Ramsay A, et al
    Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation?
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14607.
    PubMed    


  386. SROUR SA, Lee HJ, Nomie K, Ye H, et al
    Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Br J Haematol. 2017 Apr 2. doi: 10.1111/bjh.14669.
    PubMed    


  387. CHAN KL, Blombery P, Jones K, Lade S, et al
    Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors.
    Br J Haematol. 2017;177:324-328.
    PubMed    


  388. ADAMS HJ, Kwee TC
    Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?
    Br J Haematol. 2017;177:319-320.
    PubMed    


  389. BISHTON MJ, McMillan AK, Fox CP
    Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.
    Br J Haematol. 2017;177:320-321.
    PubMed    


    March 2017
  390. EYRE TA, Osborne WL, Gallop-Evans E, Ardeshna KM, et al
    Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14665.
    PubMed    


  391. NASTOUPIL LJ, McLaughlin P, Feng L, Neelapu SS, et al
    High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14541.
    PubMed     Abstract available


  392. CHEN RW, Li H, Bernstein SH, Kahwash S, et al
    RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
    Br J Haematol. 2017;176:759-769.
    PubMed     Abstract available


    February 2017
  393. MYLAM KJ, Michaelsen TY, Hutchings M, Jacobsen Pulczynski E, et al
    Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study.
    Br J Haematol. 2017;176:671-673.
    PubMed    


    January 2017
  394. RUBIO-GONZALEZ B, Zain J, Rosen ST, Querfeld C, et al
    Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
    Br J Haematol. 2017;176:16-36.
    PubMed     Abstract available


    June 2016
  395. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Abstract available


    April 2016
  396. BARTA SK, Joshi J, Mounier N, Xue X, et al
    Central nervous system involvement in AIDS-related lymphomas.
    Br J Haematol. 2016 Apr 7. doi: 10.1111/bjh.13998.
    PubMed     Abstract available


    August 2015
  397. SHARMA POUDYAL B, Gyawali B, Tuladhar S, Kapali K, et al
    Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal.
    Br J Haematol. 2015 Aug 25. doi: 10.1111/bjh.13645.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: